Pursuing Hybrid Funding Models With Silence Therapeutics' Craig Tooman
Growing a biotech company from the ground up takes more than solid science. Without the funding and structure needed to break through a competitive and volatile market, many nascent companies and promising therapeutics can stall out well before reaching their commercial potential.
Craig Tooman, president and CEO of Silence Therapeutics, has spent decades working on securing funding for a range of companies both large and small. Silence has pioneered the design and development of short interfering RNAs (siRNAs), which target and “silence” specific disease-associated genes in cells using the body’s natural process of RNA interference. But for Tooman, it’s the company’s approach to finance that stands to help its pioneering science achieve ultimate success. Tooman recently sat down with The Business of Biotech podcast to explore his own approach to weathering an uncertain market, as well as how Silence is innovating across its business.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.